Skip to content

Prevention of Sleep Apnea After General Anaesthesia With a MAD

Prevention of Sleep Apnea After General Anaesthesia With a Mandibular Advancement Device: a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04731168
Acronym
PoMAD
Enrollment
100
Registered
2021-01-29
Start date
2021-02-01
Completion date
2023-10-31
Last updated
2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peri-operative Medicine, Sleep Apnea

Brief summary

Sleep apneic episodes increase after general anaesthesia up to the third postoperative night. A mandibular advancement device, called MAD, is a small device that is inserted in the patient's mouth during the night and allows the advancement of the mandible, preventing sleep apneic episodes. The objective of this randomized controlled trial is to determine whether a MAD reduces the impact of general anaesthesia on the increase of the sleep apneic episodes in the postoperative period. All patients will have their sleep-related respiratory data measured using a portable respiratory polygraphy recorder (ResMed Embletta® system). This portable recorder allows a non-invasive recording of nasal airflow through a nasal cannula, oxygen saturation (SpO2) via finger pulse oximetry, respiratory efforts through thoracic and abdominal belts, and body position.

Interventions

DEVICEMandibular advancement device

Patients will have a mandibular advancement device during the first postoperative night

Sponsors

Centre Hospitalier Universitaire Vaudois
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- adult patient undergoing any lower limb surgery

Exclusion criteria

* continuous positive airway pressure (CPAP) treatment for obstructive sleep apnoea, * presence of severe respiratory or cardiovascular disease * preoperative consumption of benzodiazepine, * chronic use of opioids \> 30 mg/day morphine equivalent * no tooth * patient known for malignant hyperthermia

Design outcomes

Primary

MeasureTime frameDescription
Supine AHIPostoperative night 1Apnea-Hypopnea index in the supine position

Secondary

MeasureTime frameDescription
OAIPostoperative night 1Obstructive apnoea index: the number of apnoea from an obstructive origin per hour of recording
CAIPostoperative night 1Central apnoea index: the number of apnoea from a central origin per hour of recording
Hypopnea indexPostoperative night 1Hypopnea index: the number of hypopnoea per hour of recording
Global AHIPostoperative night 1Gobal Apnea-Hypopnea index: the number of apnoea and hypopnoea per hour of recording
Respiratory RatePostoperative night 1Respiratory Rate
Percentage of supine timePostoperative night 1Percentage of supine time
ODIPostoperative night 1Obstruction desaturation index: number of oxygen desaturation (≥3%) episodes per hour of sleep.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026